Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients
Dae Cheol Kim, Ki Uk Kim, Young Zoon Kim
J Korean Neurosurg Soc. 2016;59(1):26-36.   Published online 2016 Jan 20     DOI: https://doi.org/10.3340/jkns.2016.59.1.26
Citations to this article as recorded by Crossref logo
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide
Alexandra McAleenan, Claire Kelly, Francesca Spiga, Ashleigh Kernohan, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Tomos Robinson, Sebastian Brandner, Claire L Faulkner, Christopher Wragg, Sarah Jefferies, Amy Howell, Luke Vale, Julian P T Higgins, Kathr
Cochrane Database of Systematic Reviews.2021;[Epub]     CrossRef
MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review
Sebastian Brandner, Alexandra McAleenan, Claire Kelly, Francesca Spiga, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Claire L Faulkner, Christopher Wragg, Sarah Jefferies, Julian P T Higgins, Kathreena M Kurian
Neuro-Oncology.2021;[Epub]     CrossRef
Investigating DNA Methylation of SHATI/NAT8L Promoter Sites in Blood of Unmedicated Patients with Major Depressive Disorder
Hajime Miyanishi, Kyosuke Uno, Mina Iwata, Yuu Kikuchi, Hidenaga Yamamori, Yuka Yasuda, Kazutaka Ohi, Ryota Hashimoto, Kotaro Hattori, Sumiko Yoshida, Yu-ichi Goto, Tomiki Sumiyoshi, Atsumi Nitta
Biological and Pharmaceutical Bulletin.2020; 43(7): 1067.     CrossRef
Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival
Rikke H Dahlrot, Pia Larsen, Henning B Boldt, Melissa S Kreutzfeldt, Steinbjørn Hansen, Jacob B Hjelmborg, Bjarne Winther Kristensen
Journal of Neuropathology & Experimental Neurology.2019; 78(7): 633.     CrossRef
Biomarkers and therapeutic advances in glioblastoma multiforme
Andrew Octavian Sasmita, Ying Pei Wong, Anna Pick Kiong Ling
Asia-Pacific Journal of Clinical Oncology.2018; 14(1): 40.     CrossRef
Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients
Guoqiang Yuan, Liang Niu, Yinian Zhang, Xiaoqing Wang, Kejun Ma, Hang Yin, Junqiang Dai, Wangning Zhou, Yawen Pan
Journal of Neuro-Oncology.2017; 133(1): 193.     CrossRef
Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter
Jinho Kim, Sung-Hun Lee, Ji Hwan Jang, Mee-Seon Kim, Eun Hee Lee, Young Zoon Kim
Journal of Neurosurgery.2017; 126(5): 1461.     CrossRef
DNA methylation/hydroxymethylation in melanoma
Siqi Fu, Haijing Wu, Huiming Zhang, Christine G. Lian, Qianjin Lu
Oncotarget.2017; 8(44): 78163.     CrossRef
The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis
Hailong Zhao, Shuying Wang, Chengwei Song, Yunhong Zha, Li Li
World Journal of Surgical Oncology.2016;[Epub]     CrossRef